FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)

NCT ID: NCT03422510

Last Updated: 2020-08-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 33 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-04-15
• Study Completion Date: 2020-07-31

Brief Summary

This is a multicenter, open label, randomized study investigating two dose titration regimens of CXA-10 in subjects at least 18 years of age with primary FSGS.

The study will be performed at approximately 25 study centers across the United States of America (USA). The recruitment period is anticipated to be up to approximately 16 months. Approximately 30 subjects will be randomized to ensure 26 subjects complete the study. An optional 9 month open label is available

Detailed Description

This is a multicenter, open label, randomized study investigating two dose titration regimens of CXA-10 in subjects at least 18 years of age with primary FSGS.

The study will be performed at approximately 25 study centers across the United States of America (USA). The recruitment period is anticipated to be up to approximately 16 months. Approximately 30 subjects will be randomized.

Study participation for each subject will last up to 5 months. The study will consist of a screening period not to exceed 30 days (1 month), 90-day (3 month) treatment period, and an approximate 28-day (1 month) follow-up period after the last dose of study medication. An optional 9 month open label is available.

Conditions

Primary Focal Segmental Glomerulosclerosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Regimen 1 - CXA-10 75 mg

Subjects in regimen 1 will start at 75 mg and may stay at 75 mg or increase to 150 mg. This treatment arm stays at 75 mg.

Group Type: EXPERIMENTAL

CXA-10

Intervention Type: DRUG

CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)

Regimen 1 - CXA-10 150 mg

Subjects in regimen 1 will start at 75 mg and may stay at 75 mg or increase to 150 mg. This treatment arm increases to 150 mg.

Group Type: EXPERIMENTAL

CXA-10

Intervention Type: DRUG

CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)

Regimen 2 - CXA-10 150 mg

Subjects in regimen 2 will start at 150 mg and may stay at 150 mg or increase to 300 mg. This treatment arm stays at 150 mg.

Group Type: EXPERIMENTAL

CXA-10

Intervention Type: DRUG

CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)

Regimen 2 - CXA-10 300 mg

Subjects in regimen 2 will start at 150 mg and may stay at 150 mg or increase to 300 mg. This treatment arm increases to 300 mg.

Group Type: EXPERIMENTAL

CXA-10

Intervention Type: DRUG

CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)

Interventions

CXA-10

CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. have a diagnosis of primary FSGS confirmed with biopsy.

2. eGFR or 24-hour creatinine clearance ≥ 40 mL/min/1.73 m2 at Screening.

3. The subject has a Up/c ratio ≥ 2 g protein/g creatinine based on a 24 hour urine sample collected during Screening (one 24-hour collection between Day -30 and Day -8).

4. Unless there is an allergy or intolerance, subject must be on an ACEi and/or ARB regimen for a minimum of 4 weeks prior to their screening Up/c assessment. The ACEi and/or ARB regimen must be stable for a minimum of 2 weeks prior to screening Up/c assessment (and there are no plans to change the ACEi/ARB regimen over the course of the study).

5. If receiving simvastatin containing products: simvastatin (Zocor), Vytorin, or any other combination therapy containing simvastatin, the simvastatin dose should not exceed 20 mg/day.

6. Non-pregnant, non-lactating, female of childbearing potential who agrees to use a reliable method of contraception or female is of non-childbearing potential defined as surgically sterile (hysterectomy or bilateral tubal ligation) or post-menopausal.

Exclusion Criteria

1. The subject has collapsing variant of FSGS on renal biopsy.

2. The subject has secondary FSGS.

3. The subject has diabetic nephropathy.

4. The subject has any other form of acquired (including biopsy proven obesity-induced FSGS) or hereditary glomerular nephropathy.

5. The subject has a prolonged QTcF interval.

6. The subject is hypertensive.

7. The subject has a history of clinically significant cardiovascular events, arrhythmias, recurrent fainting, palpitations, or family history of congenital prolonged QT syndromes or sudden unexpected death due to a cardiac reason.

8. The subject has any known bleeding disorders or significant active peptic ulceration in the opinion of the investigator that precludes enrollment into this study.

9. The subject has clinically significant anemia in the opinion of the investigator that precludes enrollment into this study.

10. The subject has a history of any primary malignancy, including a history of melanoma or suspicious undiagnosed skin lesions, with the exception of the following:

1. Basal cell or squamous cell carcinomas of the skin,

2. Cervical carcinoma in situ,

3. Other malignancies curatively treated and with no evidence of disease for at least 5 years, or

4. Prostate cancer which is not currently or expected, during the study, to undergo radiation therapy, chemotherapy, and/or surgical intervention, or to initiate hormonal treatment.

11. The subject has a history of organ transplantation.

12. The subject has a history of HIV.

13. At the time of Screening (Visit 1), the subject has any co-existing disease or condition.

14. Since the time of presentation of symptoms/diagnosis of FSGS: the subject has received systemic (oral or parenteral) high-dose, long-term corticosteroid therapy (prednisone or alternative glucocorticoid) to treat kidney disease

15. Subject has a history of immunosuppressant therapy (calcineurin inhibitors, rituximab, or other non-steroid immunosuppressants).

16. The subject has a history of herbal or natural medication use (including fish oil) within 2 weeks or 5 half-lives, whichever is longer, prior to Baseline

17. The subject is currently taking a drug that may affect the measurement of serum creatinine (e.g. cimetidine, Bactrim, Pyridium).

18. The subject is currently taking a newly prescribed drug or new prescription for an increased dose of an existing drug that is known to prolong the QTc interval and has been associated with Torsades de pointes (a list is provided in Appendix H). Note: Stable doses of these drugs are permitted (i.e., subject has received the same dose and regimen for at least 30 days prior to Screening [Visit 1] with no anticipated changes to the dose or regimen during the study).

19. The subject is currently taking endothelin receptor antagonists, dimethyl fumarate (Tecfidera™), orlistat, fibrates (fenofibrate, bezafibrate, gemfibrozil and ciprofibrate), niacin or lomatapide.

20. The subject has any of the following abnormal laboratories at Screening:

1. Serologic evidence of HIV, hepatitis B, or hepatitis C based on HIV antibody, HBsAg, and HCV Ab,

2. Absolute lymphocyte counts below the lower limit of normal of the reference range

3. Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 3.0X upper limit of normal (ULN), alkaline phosphatase > 2X ULN of liver origin, and total bilirubin >2X ULN. If all LFTs are within normal limits (WNL) and total bilirubin is elevated, examination of direct and indirect bilirubin may be conducted to evaluate for Rotor's/Gilbert's Syndrome. Subjects with Rotor's/Gilbert's Syndrome may be enrolled.

21. Female subject with a positive urine beta-human chorionic gonadotropin (β-hCG) test at Screening (Visit 1) (all females) or Baseline (Visit 2) (females of childbearing potential or with a history of bilateral tubal ligation in the absence of documented menopause).

22. The subject has received a live attenuated vaccine within 6 weeks prior to Baseline (Visit 2) or plans to receive a live attenuated vaccine during the study period.

23. The subject has a recent history (within one year prior to Screening [Visit 1]) of abusing alcohol or illicit drugs (including marijuana) or history of extensive illicit intravenous drug use.

24. Any other condition and/or situation that causes the Investigator to deem a subject unsuitable for the study (e.g., due to expected study medication non-compliance, inability to medically tolerate the study procedures, or a subject's unwillingness to comply with study-related procedures).

25. The subject has known hypersensitivity to CXA-10, its metabolites, or formulation excipients.

26. The subject has had treatment with any investigational drug or device within 30 days or 5 half-lives (whichever is longer) prior to Screening (Visit 1) (this includes investigational formulations of marketed products, inhaled and topical drugs), or plans to participate in another investigational drug or device study at any time during this study.

27. The subject weighs < 40 kg

• Minimum Eligible Age: 13 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Kidney Research Network, formerly NephCure Accelerating Cures Institute

UNKNOWN

Sponsor Role: collaborator

Medpace, Inc.

INDUSTRY

Sponsor Role: collaborator

MicroConstants

UNKNOWN

Sponsor Role: collaborator

Arkana Labs

UNKNOWN

Sponsor Role: collaborator

NephCure Kidney International

UNKNOWN

Sponsor Role: collaborator

Complexa, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Theodore Danoff, MD

Role: STUDY_DIRECTOR

Complexa, Inc.

Locations

Alabama Neurology Consultants

Huntsville, Alabama, United States

Cedars Sinai Medical Center

Los Angeles, California, United States

Stanford University

Palo Alto, California, United States

A.I. duPont Hospital for Children

Wilmington, Delaware, United States

University of Miami

Miami, Florida, United States

Nephrology Associates of Northern Illinois and Indiana (NANI)

Chicago, Illinois, United States

Northwest Louisiana Nephrology

Shreveport, Louisiana, United States

Kidney Care and Transplant Services of New England

Springfield, Massachusetts, United States

University of Michigan

Ann Arbor, Michigan, United States

St. Clair Nephrology Research

Roseville, Michigan, United States

Clinical Research Consultants-KCMO

Kansas City, Missouri, United States

Albert Einstein College of Medicine, Montefiore

The Bronx, New York, United States

Metrolina Nephrology Associates

Charlotte, North Carolina, United States

Levine Children's Hospital

Charlotte, North Carolina, United States

Cleveland Clinic

Cleveland, Ohio, United States

Northeast Clinical Research Center (NCRC)

Bethlehem, Pennsylvania, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Nephrology Associates

Franklin, Tennessee, United States

Texas Tech

Amarillo, Texas, United States

Renal Disease Research Institute

DeSoto, Texas, United States

El Paso Medical Research

El Paso, Texas, United States

Virginia Commonwealth University

Richmond, Virginia, United States

The Polyclinic

Seattle, Washington, United States

Providence Sacred Heart Medical Center and Children's Hospital

Spokane, Washington, United States

Countries

United States

Other Identifiers

CXA-10-204

Identifier Type: -

Identifier Source: org_study_id